Work

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.tps7615

Authors: Michael J. Boyer, Pasi A. Janne, Tony Mok, Kenneth John O'Byrne, Luis G. Paz-Ares, Suresh S. Ramalingam, Jane Q Liang, Ian Taylor, Alicyn Campbell, Joseph P. O'Connell, Stephen P. Letrent, Vladan Antic

Institutions: Dana-Farber Cancer Institute, Chinese University of Hong Kong, St. James's Hospital, Hospital Universitario Virgen del Rocío, Emory University, Winship Cancer Institute, Pfizer (United States), Pfizer (Switzerland)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599891007

Cites:

Cited by: 14

Related to: 10